Astrazeneca

 Page 2 

LATEST

Bid for AstraZeneca shows how boards feel swamped by short-term thinking

Merge lanes road sign

Here is some excellent advice from an old hand to the directors of AstraZeneca should Pfizer, as expected, get serious about bidding and increase its current £48-a-share offer: don't be swayed by the views of investment bankers chasing success fees; don't judge bid premiums based on a two- to three-year view; and remember you have responsibilities beyond price.

HOT LIST

FEATURED